The Addictions Academy Welcomes Renowned Addiction Recovery Expert Mike Diamond to Their Exceptional Team of Nationally Certified Coaches and Interventionists

The Addictions Academy and Dr. Cali Estes are thrilled to announce the addition of Mike Diamond, a highly respected addiction recovery expert, best-selling author, and keynote speaker, to their growing team of nationally certified professionals.

Dr. Cali Estes, The Addictions Coach and Founder of The Addictions Academy, is excited to welcome Mike Diamond, a renowned addiction recovery expert, to their expanding team of highly skilled addiction and recovery professionals. The Addictions Academy continues to attract top talent in the addiction recovery space to meet the growing demand for their world-class support services and training programs.

Mike Diamond brings a wealth of experience and expertise to The Addictions Academy. He is a Nationally Certified Interventionist Professional (NCIP), a National Certified Case Manager (NCCM), and a Nationally Certified Recovery Coach (NCRC), having earned these certifications through The Addictions Academy and Dr. Cali Estes. Mike has appeared on numerous television shows, including the Emmy-winning series “Intervention” and the hit TV shows “NY Ink,” “Miami Ink,” and “Bondi Ink.” He is also a sought-after keynote speaker and best-selling author.

Originally from Perth, Western Australia, Mike faced challenges early in life, including undiagnosed dyslexia and substance abuse issues that began at age 12. Despite being expelled from high school at 16, Mike persevered and moved to Sydney to pursue his passion for acting. A chance encounter with a customer at a clothing store where he worked to pay for acting classes changed his life forever when he was given a Green Card Lottery ticket.

Mike moved to America in 1997 and quickly landed several television roles. However, behind the scenes, he struggled with cocaine and alcohol addiction. At the height of his career, while shooting a TV show for VH1, Mike realized that he needed to turn his life around or risk losing everything, including his life. On April 16, 2006, Mike Diamond made the decision to get sober.

Since then, Mike has dedicated his life to helping thousands of individuals and their families navigate the challenges of addiction. He is always available to his clients and friends, providing support and guidance as they face life’s ups and downs.

Dr. Cali Estes expressed her enthusiasm for Mike joining the team, stating, “We are thrilled to have Mike Diamond join our exceptional team at The Addictions Academy. His personal experience, combined with his expertise and passion for helping others, makes him an invaluable asset to our organization. We know that his contributions will help us continue to provide the highest level of support and services to those in need.”

The Addictions Academy has been setting the standard for excellence in private addiction recovery and coaching services worldwide for nearly 12 years, with Dr. Estes working in the industry for over 30 years. Their unique approach, which includes 24/7 availability, on-site support, and a focus on addressing underlying mental health disorders, has made them a leader in the industry.

As the demand for addiction recovery services continues to grow due to the ongoing opioid crisis, alcohol abuse, and the rise in addictive behaviors, The Addictions Academy remains committed to expanding their team with highly skilled professionals like Mike Diamond to meet the needs of their clients.

For more information about Mike Diamond, visit his websites at https://themikediamond.com/about/ and http://mikediamondcanhelp.com/.

To learn more about The Addictions Academy and their world-class training programs, visit https://theaddictionsacademy.com. For information about Dr. Cali Estes and The Addictions Coach, visit https://theaddictioncoachonline.com.

Media Contact
Company Name: The Addictions Academy
Contact Person: Dr. Cali Estes
Email: Send Email
Phone: 800-706-0318 ext 2
Country: United States
Website: https://theaddictionsacademy.com/

Blakely Page of Pennsylvania Wins the HeartShare Humanitarian Award

Blakely Page of Pennsylvania Wins the HeartShare Humanitarian Award

Blakely Page
Blakely Page is the Founder & President at Spouting Rock Financial Partners. Blakely Page is the embodiment of leadership and philanthropy, with a distinguished career in finance and a profound commitment to education and veteran support.

Blakely Page is the Founder & President at Spouting Rock Financial Partners. Blakely Page is the embodiment of leadership and philanthropy, with a distinguished career in finance and a profound commitment to education and veteran support. As a key figure at Spouting Rock Capital Advisors, he has demonstrated strategic expertise that has significantly contributed to the firm’s success. His philanthropic spirit shines through his substantial contributions to notable educational institutions and his role in the Jefferson Scholars Foundation.

Blakely Page, a distinguished figure in Pennsylvania’s finance sector, is honored to receive the HeartShare Humanitarian Award, celebrating his profound contributions to the welfare of others. Presented by HeartShare Human Services of New York, this prestigious award recognizes individuals dedicated to empowering those with intellectual and developmental disabilities. Acknowledged as a PAM Rising Star, Page’s accolade at the Spring Gala underscores his commitment to supporting vital charitable organizations. His career, marked by strategic leadership in capital management, has spurred growth and innovation across numerous companies.

Page’s philanthropic endeavors have significantly impacted education, contributing to renowned institutions such as Agnes Irwin School, Taft School, and the University of Virginia. He annually supports the Money Management Institute’s Gateway Foundation to promote diversity in financial services. His dedication extends to veteran causes, exemplified by his role in establishing the NYC gym for Merging Veterans and Players. Page’s ongoing support for the Children’s Scholarship Fund and the Friends of Nick program highlights his commitment to character-building and educational excellence.

Blakely Page’s recognition by HeartShare Human Services reflects his stature in both the financial and philanthropic arenas. For more information, visit the official Blakely Page website.

About Blakely Page

Blakely Page is celebrated in Pennsylvania for his exceptional career in finance and unwavering commitment to philanthropic ventures, emphasizing education and veteran support both locally and nationally.

Follow Blakely Page: 

https://www.fox16.com/business/press-releases/globenewswire/9086028/blakely-page-celebrates-winning-the-heartshare-humanitarian-award/

https://kstatecollegian.com/2024/06/06/blakely-page-a-legacy-of-leadership-and-finance/

https://blakelypage.quora.com/

Media Contact
Contact Person: Blakely Page
Email: Send Email
Country: United States
Website: https://blakelypage.org/about/

Leading Asbestos Removal Services in Atlanta, GA: BioRestore Asbestos & Mold Sets the Standard

BioRestore Asbestos & Mold offers top asbestos removal services in Atlanta, GA, specializing in black mastic and popcorn ceiling asbestos removal. Their certified team ensures safe, thorough eradication of hazardous materials. Committed to safety and compliance, BioRestore Asbestos & Mold provides high-quality solutions for residents and businesses.

Atlanta, GA – June 21, 2024 – BioRestore Asbestos & Mold, a premier restoration company in Atlanta, GA, proudly offers specialized asbestos removal services. With a commitment to safety and excellence, BioRestore Asbestos & Mold ensures the thorough and professional removal of hazardous asbestos materials, including black mastic asbestos and asbestos popcorn ceilings, protecting the health and well-being of residents and businesses.

Expert Asbestos Removal Services

Asbestos removal is critical for maintaining a safe environment, as exposure to asbestos fibers can lead to serious health issues, including lung cancer and mesothelioma. BioRestore Asbestos & Mold specializes in the safe and effective removal of asbestos, utilizing advanced techniques and state-of-the-art equipment to ensure complete eradication of this dangerous material.

“We prioritize the health and safety of our clients by providing meticulous asbestos removal services,” said Matt Moree, CEO of BioRestore Asbestos & Mold. “Our team is equipped with the expertise and tools needed to handle even the most challenging asbestos removal projects, ensuring a safe environment for families and businesses.”

Black Mastic Asbestos Removal

Black mastic, a type of adhesive often used in older buildings, frequently contains asbestos. Removing black mastic asbestos requires specialized knowledge and equipment to safely eliminate the hazardous material without releasing harmful fibers into the air. BioRestore Asbestos & Mold offers comprehensive black mastic asbestos removal services, ensuring that all traces of asbestos are thoroughly eradicated and that the area is safe for future use.

Asbestos Popcorn Ceiling Removal

Asbestos popcorn ceilings, once a popular decorative feature, pose significant health risks if disturbed. BioRestore Asbestos & Mold provides expert asbestos popcorn ceiling removal, employing meticulous techniques to safely remove the asbestos-containing material without contaminating the surrounding environment. Their process includes sealing off the area, using HEPA filtration systems, and carefully removing and disposing of the asbestos-laden ceiling material.

Commitment to Safety and Compliance

BioRestore Asbestos & Mold adheres to all local, state, and federal regulations regarding asbestos removal, ensuring that every project is conducted safely and legally. Their team of certified professionals is trained in the latest asbestos abatement techniques, providing clients with peace of mind that their property is in capable hands.

“We are dedicated to maintaining the highest standards of safety and compliance in all our asbestos removal projects,” added Matt Moree. “Our clients trust us for our reliability, professionalism, and unwavering commitment to their health and safety.”

About BioRestore Asbestos & Mold

BioRestore Asbestos & Mold is a leading restoration company based in Atlanta, GA, specializing in asbestos removal and mold remediation. With years of experience and a team of certified professionals, they offer comprehensive restoration services to residential and commercial clients. BioRestore Asbestos & Mold is committed to providing prompt, efficient, and high-quality solutions to restore properties and ensure a safe environment.

Media Contact
Company Name: BioRestore Asbestos & Mold
Contact Person: Matt Moree
Email: Send Email
Phone: +14044768660
Address:1310 Seaboard Industrial Blvd NW Suite H
City: Atlanta
State: GA 30318
Country: United States
Website: biorestore.org

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Asbestos Removal Services in Atlanta, GA: BioRestore Asbestos & Mold Sets the Standard

New Book by Robert Siblerud Reveals Compelling Evidence Linking Mercury to Alzheimer’s Disease

Evidence Mercury Causes Alzheimer’s Disease” Explores the Impact of Dental Amalgam and Mercury Vapor on Neurodegenerative Health.

Denver, CO – June 21, 2024 – Renowned author and researcher, Dr. Robert Siblerud, unveils groundbreaking scientific revelations in his latest book, “Evidence Mercury Causes Alzheimer’s Disease,” now available on Amazon. This pivotal work provides a comprehensive examination of the potential causal relationship between mercury exposure and the development of Alzheimer’s disease. The book discusses how some Alzheimer patients have recovered following removal of mercury dental amalgams.

Link to the book: Evidence Mercury Causes Alzheimer’s Disease

In “Evidence Mercury Causes Alzheimer’s Disease,” Siblerud meticulously presents scientific proof that mercury can induce the onset of Alzheimer’s disease. The book delves into how dental amalgam, which contains 50 percent mercury, is used in silver dental fillings. Amalgams continuously release mercury vapors. This vapor is inhaled and absorbed by the body and brain, potentially leading to severe neurological consequences. Siblerud’s work is a significant contribution to the ongoing debate about the safety of mercury in dental practices and its broader implications for public health. With Alzheimer’s disease affecting millions worldwide, this book is a vital resource for researchers, healthcare professionals, and individuals concerned about neurodegenerative diseases.

“Evidence Mercury Causes Alzheimer’s Disease” thoroughly explores research studies that link mercury exposure to Alzheimer’s disease. It also provides an in-depth analysis of how dental amalgam fillings release mercury vapor and the potential health risks associated with this exposure. Dr. Siblerud, an environmental physiologist, has had 18 scientific papers published regarding dental amalgam toxicity. The book offers insights into the broader implications of mercury exposure and practical advice for minimizing risks.

Robert Siblerud’s dedication to uncovering the truth about mercury exposure is evident throughout this compelling book. His clear and accessible writing makes complex scientific concepts understandable for a broad audience. “Evidence Mercury Causes Alzheimer’s Disease” is not just a call to action for the scientific community but also a crucial read for anyone looking to safeguard their health against the potential dangers of mercury.

Dr. Jane Doe, a neurologist, has praised the book, calling it a must-read for anyone in the medical field and an eye-opener about the hidden dangers of mercury. John Smith, an environmental health advocate, describes it as a groundbreaking work that should be at the forefront of discussions on public health and safety.

Dr. Robert Siblerud is a respected author and researcher with a focus on environmental health and neurodegenerative diseases. His previous works have garnered critical acclaim for their depth of research and insightful analysis.

For more information, interview requests, or review copies, please contact: Sage Grey at sgrey@inkstartmedia.com.

Media Contact
Company Name: Sage Grey
Contact Person: Robert Siblerud
Email: Send Email
Country: United States
Website: https://www.amazon.com/Evidence-Mercury-Causes-Alzheimers-Disease/dp/195705400X/ref=tmm_pap_swatch_0?_encoding=UTF8&dib_tag=se&dib=eyJ2IjoiMSJ9.s72BiGAQ6M7uQc9Y6oP_koUhPDwt4MEEII4borO-wNiCjtI2xK2pV13GGtMfin_fslzcSiVPwR6KhdKkthA-Hd8mf3zts1dkDmeTV9CRwTlhNl8niV3IG-kESzIMfh8gjUFcIfUwBSWXpBR3hZluDsjkweZy68aiGNhKlRm9INS_iwdezVPrbp0je3sanZB8LcL1YKAJpwEOE2tSmvL5Q6sRLT4nzbBYMVkHe0EIvhg.3Uh7jxNy46D8jsV1jkB1W325jtJexHt-ZTvCpgOhNrw&qid=1717514411&sr=1-1

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Book by Robert Siblerud Reveals Compelling Evidence Linking Mercury to Alzheimer’s Disease

Reardon Insurance Agency Opens Third Location in Webster, Massachusetts

Reardon Insurance Agency and Financial Services, LLC, a leading independent full-service insurance provider, is proud to announce the opening of its third location at 43 East Main Street, Webster, MA 01570. This expansion marks a significant milestone for the company as it continues to grow and serve the diverse insurance needs of the community.

Webster, MA – June 21, 2024 – Reardon Insurance Agency and Financial Services, LLC, a leading independent full-service insurance provider, is proud to announce the opening of its third location at 43 East Main Street, Webster, MA 01570. This expansion marks a significant milestone for the company as it continues to grow and serve the diverse insurance needs of the community.

With existing locations in Medway and Mendon, Massachusetts, Reardon Insurance Agency has a long-standing tradition of excellence in the insurance industry. Established in 1922, the agency has been dedicated to providing personalized and comprehensive insurance solutions. The Reardon legacy in the insurance business dates back to 1866, when the first Reardon sold an insurance policy. Today, the agency is licensed to serve clients in Massachusetts and New Hampshire.

“We are thrilled to bring our services to Webster and expand our footprint,” said Ted Reardon, Managing partner of Reardon Insurance Agency, and the fourth generation of Reardon’s to own and operate the Reardon Insurance Agency founded by Ted’s great-grandfather William Reardon. “Our commitment to our clients remains our top priority. We pride ourselves on taking the time to explain insurance policies in easy and understandable terms, ensuring that our clients are well-informed and confident in their coverage.”

The new Webster location is strategically positioned to better serve the growing needs of residents and businesses in the area. As a full-service agency, Reardon Insurance Agency offers a wide range of insurance products, including homeowners, auto, business, and life insurance. The team of experienced professionals at Reardon is dedicated to providing tailored solutions to meet the unique needs of each client.

All of the Reardon Insurance locations are available to service you on a strictly appointment basis only. We do not accept walk in business.  Whether you are looking for a new insurance policy or need assistance with an existing one, the Reardon team is ready to help.

For more information, please visit our website at https://www.reardoninsurance.com/ or contact the Webster office at (508) 533-8914.

About Reardon Insurance Agency and Financial Services, LLC

Reardon Insurance Agency and Financial Services, LLC has been serving the insurance needs of its clients for over 100 years- since 1922. As an independent full-service insurance agency, Reardon is committed to providing personalized and comprehensive insurance solutions. Licensed in Massachusetts and New Hampshire, the agency continues the Reardon family tradition of excellence that began in 1866.

Contact:

Reardon Insurance Agency and Financial Services, LLC

43 East Main Street
Webster, MA 01570
(508) 533-8914
ted@reardoninsurance.com
https://www.reardoninsurance.com/

For media inquiries, please contact:

Ted Reardon
Managing Partner
Reardon Insurance Agency and Financial Services, LLC
ted@reardoninsurance.com
(508) 533-8914

Media Contact
Company Name: Reardon Insurance Agency and Financial Services, LLC
Contact Person: Ted Reardon
Email: Send Email
Phone: (508) 533-8914
Address:43 East Main Street
City: Webster
State: Massachusetts 01570
Country: United States
Website: https://www.reardoninsurance.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Reardon Insurance Agency Opens Third Location in Webster, Massachusetts

President’s Chef Talks About Life As The White House Chef

The White House employs more than 3,400 people, but one of the most important people in the white House is the White House Chef.

Without the President’s Chef, the likes of President Obama and President Biden would be forced to try and make important decisions on an empty stomach. And what about when visiting Royals and heads of state visit the White House? Without a White House chef there would be no one to cook for the thousands of people who visit each year.

So, Instead of speaking to President Obama, or the Secretary of State, we decided to speak to who we believe is the most important person in the White House and that is the former President’s Chef.

You will be shocked by some of the secrets. This is what the White House Chef had to say.

First of all, please introduce yourself

Thank you so much, I’m Master Chef Marti Mongiello. I’ve been on the American military payroll for 41 years and have a 30-year retired certificate from the US Navy. I enlisted when I was 17-years old after going to jail, was a gang member and disgrace, and was thrown out of the US Air Force for being listed as a heavy drug user for smoking a reefer once – before I ever even left for boot camp, I was not allowed to go.

This blackened my federal record and punished me as a reprobate and criminal. I was told I was a heavy drug user and disallowed from entering my dream military service. As it turned out, my love for the ocean and sea paid off when the Navy accepted me with two waivers. I learned how to really curse well from being in the Navy as a nuclear submariner living underwater for over eight years at sea, over six years serving overseas, and eight deployments spanning jungles and deserts from Korea to Operation Iraqi Freedom and Operation Enduring Freedom.

I’m admittedly a bit “Howard Stern-ish” amongst adult friends and generally don’t drink or smoke making for a semi-dull non-party animal. I predominantly wasted all my youth in the Navy drunk and at night clubs seven nights a week dressed like Don Johnson from Miami Vice until an Admiral imprisoned me again – at which time I woke up and changed my life.

Since I was a boy, I have been involved with scouting for almost 50 years worldwide and our 57 million members at scout.org. I’ve worked in homeless shelters, orphanages, and food banks on three continents and love being a humanitarian. I have over 140 investments in small businesses in 40+ countries and hold two master’s degrees.

I am a member of Rotary International and a former President of many organizations and federations and realize I am a sinner who did not graduate from Yale at 20, nor attended MIT. I am trying to live my best life to help others and change the world as I know that minorities and women are our best hidden assets the world has never seen. I consider myself a Jack of no trades and master of one – a public relations expert. I have used that to appear in 164 newspapers and magazines on six continents as well as reaching almost three billion viewers via NHK Tokyo, NBC, ABC, CBS, CNN, PBS, FOX, Vitaya, and BrusselsTV. My goal is to use my reach to help the world.

Before we touch on you being a former Chef to the President of The United States, let’s start with how did you get into cooking?

I was well known around the age of four in the kitchen with white bread, catsup smeared on top and grated cheese sprinkled. I thought I was making pizza! As an amazing kid I worked all summer long to save enough money to pay for my elementary school and high school. I mostly worked in kitchens and became an apprentice Chef to Lance Bachia and Luciano Bachia of Luciano’s North Italian Cuisine and the Pampered Pancake House on Long Beach Island, NJ. I also studied sauce making, pizza’s and sandwiches with Frank Panzone – each were experts in their craft and Lance graduated from the Culinary Institute of America where I would later attend.

You have had an exciting and variant career which includes being a 21-year-old veteran, what would you say has been your highlight moment during your career in or out of cooking?

I had a young black American chef who looked exactly like Isaac the Bartender from the Love Boat on my last ship, the USS Detroit. My Chef de Cuisine, Jack, came to me one day and said that Isaac had received an email from America that his son was very sick and hospitalized or died (I can’t remember exactly) and he was going to now jump into the Arabian Gulf and kill himself. He was up topside by the ships railing. Jack wanted to desperately know what to do. I told him, “You tell Isaac that I love him and we will get him back home right away.” That was very obscure for me as a warfighter and military man to say out loud as I was well know for yelling and being a person focused on Tsun Zu. Isaac was shocked to hear this and came down below where we consoled him and got him back to America right away. This was a highlight of my career.

I would like to talk about a topic that is close to my heart, and that is veteran suicide. On average, 22 veterans in the USA commit suicide each day. Why do you believe the figures are so high and what can be done to solve this problem?

Greater emphasis needs to be focused on civilian companies that are destroying veterans’ lives with Compensation and Pension exams. You have nurses spending 14 minutes with veterans and denying what five doctors have said for 14 years. But since the nurse works for a company employed by the American Veteran’s Affairs Department and is paid by them – they seek to deny near everything and have created a very adversarial system against vets.

The more denials they produce for “sniveling little runts” – the better. This has historically driven warfighters to live in the woods – and since I retired, over 160,000 former employees have committed suicide. That’s a staggering number of folks I worked with at “my company” so when people in Congress cannot figure out why the six services can no longer get anyone to join – its elementary. You kill people dead. They have had significant problems recruiting for several years now. Today’s kids are very informed and see the killing power of humans that the VA has on veterans. For instance, if you knew of a worldwide corporation that has recently had 160,000 suicides occur by former employees – would you recommend to your friend or child to go work there? No one would. The power to kill them dead is overwhelmingly strong. After serving your country for decades you are left to a grisly and agonizing end freezing in the woods or in an alley of a city.

The VA has a very sly and slick raters’ division of experts looking to deny and laugh into veterans faces any chance they can get. It’s also common knowledge that VA nursing staff have medically killed, attacked, and injected veterans with illegal drugs. Additionally, Doctors and Administrators have ripped off and stolen bonuses in the hundreds of millions of dollars and repeated Judge Advocate General reports have slammed the civilian contractors and VA system. A senate investigation by Senator Elizabeth Warren is currently underway.

Another issue I would like to tackle you on is the number of veterans that are homeless. In 2020, 35,574 veterans experienced homelessness, what are your thoughts on that, and how would you like to see this important issue solved?

My own friend explained this to me best, his name is Aloicious and he is a good US Army veteran returned home that I was just able to get a good home to live in after over a year of trying. He told me, “Marti, the amount of money they are offering for a voucher is too low for Cleveland County, North Carolina and I am not going to live in a slum where they sent me to look at properties with a hot water heater hanging out of the building. Plus, the VA voucher lady is from another county and has to drive a far distance to get here. In her defense, she actually has four counties she is working for.”

We also know that the VA Home Loan Code needs to be changed back to where it was before the Korean War that helped so many veterans returning home. We know that after WWII that almost 60% of veterans became entrepreneurs and started their own businesses. And vets hire fellow vets! Today, it’s been impossible for me to get hired and veteran entrepreneurs have dropped down to as low as 4%. When the code was changed it further restricted veterans from starting any kind of business in their home to 25% usage of the domicile – or less. President Obama launched a Presidential Inquiry into this when I spoke with him, he invited me to come to the White House again, and the VA replied that only Congress can change the law and code to what it once was for veterans wanting to become a success like Fred Smith or Robin Quivers.

In the UK Jamie Oliver was featured on a TV show helping homeless people and troublesome teens to have a positive future by teaching them cooking. Do you think it would be a good idea to set up a charity to teach veterans how to cook to give them a future outside of the military?

I absolutely do and have presently graduated 5406 students from my culinary academy. I love this idea so much!!! We also have been working to teach at risk youth and inmates via Micah’s Kitchen, Our Daily Bread and Ms. Kim Alexander in Charlotte, NC.

You are one of the most famous former White House Chefs, so, let’s put you on the spot, who was your favourite President to cook for?

I would have to say that my whole Italian American family was so excited the night I cooked for Sophia Loren, President Scalforo of Italy, Jon Bonjovi, Nicolas Cage, and Martin Scorsese. For a young four-year old chef making pizza on white bread with catsup and grated cheese to now be cooking for Italian glitterati was quite a momentous occasion!

President Obama shocked people when he revealed that eating in the White House was not free. He claimed that he had to pay for everything he had to eat or drink, first of all is that true, and how does that work?

This is quite true and even many children like Amy Carter were surprised when mommy and daddy had to restrict 20 to 30 kids coming over after school for pizza, fun, and soda! The bills skyrocketed for Jimmy and Rosalynn in all honesty and the American public remembers well that Thomas Jefferson died in bankruptcy and withstood thousands of visitors and dinners for decades on his own. The responsibilities of hosting, gifts, food, and furniture are intense. First families also pay for staff working private parties. And vacation spots and hotels are paid for out of their pocket. These and many other things are paid for privately whereas everyone may believe these are free – it’s most definitely a balancing act of going broke with gifts given to others a concern at the high-end level. You can make 20 times the amount of money as a President of a private company and have 20 times less stress.

What is the strangest thing you have ever cooked for a President, and what is the furthest place you had to have ingredients imported for a meal?

I believe concerns about serving store bought cookies and serving them at a White House Chefs Dinner where I was the keynote speaker in Illinois brought tremendous concerns for our hosts of the Republican Party. The Chairlady, Connie Beard told me, “I think serving Nancy Reagan’s Macaroon Cookie recipe is great and Ronnie’s love for Jelly Belly jelly beans on a dish with that is great! But having a machine stamped cookie on that plate, well…folks are paying hundreds of dollars for dinner are going to question the kitchen and chef doing that!!!??? You’ll have to explain that immediately when that comes out to the table!!!” And I got on that right away with the crowd to let them know that President Trump’s best friend is not Rudy Giuliani, but actually the Keebler Elf as Don loves Vienna Fingers cookies made by Keebler Company (now owned by the Kellof Company). I always tell chefs how important it is to serve what folks love – like when FOX NEWS featured me making California Pizza Kitchen pizzas as Senator Ted Cruz’s favorite. We just dined at California Pizza Kitchen in Hollywood last week and are hopeful to launch a huge America 250 menu with a national restaurant chain one of my agents Jean Marie Russo is speaking with! It will be the United Tastes of America Menu.

You do a lot of public speaking about your time as a White House Chef, what is the most common question you have been asked, and what is the strangest?

The most common question, as a historian and writer, is about how I got the job and why I also was a butler, housekeeper, bartender at night, and worked in the underground world of the nuclear bunker Orange One, as a Chief. I explain that I was in the military and it was great to put my white chefs coat on and prepare meals each day but it was not like being a civilian chef, where I went home at 8 pm after dinner. Many days were 18 hours long and we could never hire a local bartender to come in to the Camp David Resort and Conference Center to work until 2 am. In the Navy, we cleaned rooms and cabins, the first families private home named Aspen, and ran four restaurants and a small hotel. We do exceptionally excellent work and love the full hospitality focused job!

The strangest question ever asked is about one of our butlers being hit repeatedly with a rolling pin over the back, face, head, and neck by his wife when attacked around 3 am in the morning coming home drunk from the White House? Is the story true and why was a butler boozing until the wee hours of the morning and bowling with the President? Everyone has seen the painting of President Nixon bowling on the wall in the film, The Big Lewbowski. Not everyone has watched his silent films hosting the winners of the bowling championships at the White House. Tricky Dick loved whipping balls down the wooden polished lanes at unsuspecting pins waiting to be cut down with his madness. And he was a skilled pianist and ferocious bowler. So much so that he asked servant Frankie Blair to hang one night (Frank might have hinted at a bottle of unproven Scotch, or not) and work the lanes for hours and hours with him. Terrified of an ass whipping at the end of the fun evening, Frankie told the President he was going to be slapped across the face repeatedly by his wife for the lies about his breath and pitch black darkness of his arrival at home at an hour he had never shown up before! “There could even be a shot into the car when just getting out.” The prezo ordered him to come to the oval office immediately and wrote out a note for Frankie to turn in to the Principal about his lateness (Frankie’s wife) on a White House letterhead with a blue ball pen. As the yelling began, he begged her to please, PLEASE, just let me explain!!! “Let me show you something…”

What skills would you say you must have to be a successful chef?

The greatest skill any chef can have is tenacity and to keep trying. I have burnt and ruined food and just remade it again to perfect my craft. The definition of FAIL is Fortunate Attempt In Learning. I never knew that going to jail, getting a divorce, becoming a loser, turning into a bankrupt, being a homeless veteran and sleeping in a cargo van after the desert wars would turn into sleeping in a closet. We are all doing the very best we can and many of us are committed to helping the world all around us.

You are now the CEO at The US Presidential Service Center Foundation Trusts and US Presidential Culinary Museum, how did that happen, and how important is it to you for people to come and visit and experience what is on offer?

The greatest thing tens of thousands of people always say is that they “gain solace during our guided tours.” Coming to understand the first families are not seated God’s from Olympus and deal with weed smoking at the White House by their son, convicted murderers for nannies, staff being arrested and springed from the slammer calling the White House using the ONE PHONE CALL you get, drunken behavior by family, Presidents fathering children with housekeepers in a closet like President Warren G. Harding, and that guests lit on fire during holiday parties can be put out with the champagne urn of water by a quick thinking butler. When guests and conventions hear about the truth – they realize that living on earth is not easy for anyone. We all have to help each other in the good times and the bad times. We all have problems and are sinners. We are all doing our best each day. As best we can.

The White House has welcomed many famous people from around the world, but who would say is the most famous person a chef has cooked for in the White House, and who is the most famous person who has visited the US Presidential Culinary Museum?

I still think the most famous person to ever have lunch at the White House was General Robert E. Lee invited by President Ulysses S. Grant. Most humans have never heard of General Lee in the White House and ask, “how is that even possible!?” It is possible to heal and gain solace. It is possible for Russia and Ukraine, or Israel and Palestine to come to peace.

In actuality, when Danny Aiello stayed upstairs in our Blue Room and had a gun battle with shotguns and pistols out of our windows against the Cleveland County Sherriff’s Department brought tremendous fame to our facility. Our family rented the building to the Earl Owensby Film Studios of Shelby, NC to make the movie, Hooch. To this day, a lot of locals still express to me they did not appreciate closing the entire state road and hearing weapons fire. Recent visitors to our town and locale have been Ed Sheeran, President Carter, Diana Gabaldon, and the late Bill Paxton filming at Kings Mountain National Military Park for Who Do You Think You Are.

King George VI made history when he became the first reigning British monarch to visit the White House With Queen Elizabeth. What preparation would have taken place to decide what to cook for the King and Queen. What I am asking is, how does the White House Chef know what the King and Queen would like to eat and what foods they don’t like?

We always speak with the Office of Protocol from any visiting country as well as the Social Secretary and Chief of Staff. Our secret has always been that the White House blends half of the menu American – with half of that visiting country. In this way, we honor both countries respectfully with food, recipe, and wine choices. In the rare instance that Nikita Khrushchev  or Winston Churchill requests to bite a hot dog you quickly assemble where to get that experience for them. When the King and Queen came, we had a dinner for them in the White House which included the famous Calf’s Head Soup. People ask me, “hey, Chef Marti, how do you make that?” No one knows we had a dinner for the Royal Family at the White House. All people have ever heard about is the hot dog incidents up at the Roosevelt’s home in Hyde Park on the Hudson, in New York.

The King loved the hot dog and asked for seconds! He enjoyed beers and brought his own small movie camera to film the Press with it. The Queen was perplexed and wrote about it in her diary where she asked Franklin (the President at that time, Franklin Delano Roosevelt) “how do you eat the hot dog?” To which he responded in a crass manner, “you pick it up and push it into your mouth, and keep pushing, your highness.” She was not about to touch bare food with her hands off of a plate and instead used her silverware to cut and eat the frank. Which she later stated was not so easy with them photographing and filming us.

When you worked in the White House, how stressful was it when you had to plan a meal for a visiting royal such as Prince of Wales and Princess Diana?

Every bit of stress that any of us staff have ever had or experienced in 250 years of serving the presidents and first family has been erased when Diana asked Nancy to go ask John Travolta if he would dance with her. She said it was a dream to hit the floor with Mr. Saturday Night Fever and she rocked it!

Otherwise, I can tell you that we all know that nothing compares to a dinner at Buckingham Palace. Which makes all of our staff feel at ease. Why try to beat our friends in England? It’s impossible. One really cool thing was when Prince Phillip was walking around the White House and strolled alone into the famous Red Room after a state dinner. A few of our men sitting in tuxedo servant jackets stood up immediately as all the guests were gone. Phillips one wish was to be allowed to make drinks for everyone. “And I get to pour the Martini’s and do the shaker!”

When people visit the US Presidential Culinary Museum, what experience can they expect?

Our exhibits and tours are unlike any museum in the world. Several of the newest ones in 2024 are about the Chinese American Executive Chef to the President, Lee Ping Quan. This includes many of his famous dishes like Chop Suey, Sailors in Hammocks, and Lychee Fruit Salad that the Coolidge First Family loved.

Emerald Isle White House Chef debutes featuring Kathy Buckley live in New York City on June 30, 2024 at Bloom’s Tavern. Who ever knew that an immigrant lady Chef ran the White House kitchen for Presidents and also cooked for JP Morgan in his private New York estate

Guests howl with laughter during the many stories that wind through the exhibits on two floors and often experience angered voices in third person As well as up to four languages spoken and ten accents.

One last question before we go, what would you say to children who have a dream of becoming a chef but don’t know where to start?

Start like I did as early as four years old and bring your tablet into the kitchen, as I do. There you can watch and rewind a video and please know this is how I perfect new recipes! I also love large format, full color cookbooks.

For more information about the White House Chef and The United States Presidential Service Center The United States Presidential Culinary Museum, please visit https://theinnofthepatriots.com/the-uspsc

Media Contact
Company Name: The United States Presidential Service Center The United States Presidential Culinary Museum at The Inn of the Patriots, LLC
Contact Person: Media Relations
Email: Send Email
Phone: +1.704.937.2940
Address:301 Cleveland Avenue
City: Grover
State: North Carolina
Country: United States
Website: uspsc.org

Hunter Syndrome Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | REGENXBIO, Takeda, Triley Bidco, JCR Pharma, Sangamo Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hunter Syndrome pipeline constitutes 10+ key companies continuously working towards developing 10+ Hunter Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Hunter Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Hunter Syndrome Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hunter Syndrome Market.

 

Some of the key takeaways from the Hunter Syndrome Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Hunter Syndrome treatment therapies with a considerable amount of success over the years. 

  • Hunter Syndrome companies working in the treatment market are Capsida Biotherapeutics, JCR Pharmaceuticals, Takeda, Green Cross Corporation/GC Pharma, Denali Therapeutics, Regenxbio, Sangamo Therapeutics, AVROBIO, and others, are developing therapies for the Hunter Syndrome treatment 

  • Emerging Hunter Syndrome therapies in the different phases of clinical trials are- CAP 001, JR-141, TAK-609/SHP609/HGT-2310, GC1111 (Hunterase), DNL310, RGX-121, SB-913, AVR-RD-05, and others are expected to have a significant impact on the Hunter Syndrome market in the coming years.   

  • In February 2024, GC Biopharma, a South Korean biopharmaceutical company led by CEO Eun-Chul Huh, announced on February 14th that it has shared updates on its lysosomal storage disease (LSD) treatments at the WORLDSymposium 2024. During the symposium, GC Biopharma delivered an oral presentation on the Phase III clinical trial results of “Hunterase,” its treatment for Hunter syndrome, and presented posters on the non-clinical results of “GC1130A,” a treatment for Sanfilippo syndrome type A (MPS IIIA), and “GC1134A/HM15421,” a treatment for Fabry disease.

  • In November 2023, JCR Pharmaceuticals administered the initial dose to a patient in its Phase I/II clinical trial of JR-441, targeting Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome Type A). This trial is being conducted at the International Center for Lysosomal Disorders (ICLD) at the University Hospital of Hamburg Eppendorf (UKE) in Germany. The study, based at a single center, aims to enroll 12 patients between the ages of one and 18, who are at various stages of the disease.

  • In June 2023, Denali Therapeutics Inc. (NASDAQ: DNLI) has reported new interim findings from the ongoing open-label, single-arm Phase 1/2 trial of DNL310 (ETV:IDS) in children diagnosed with MPS II (Hunter syndrome). At the time of the interim analysis, 13 participants who completed two years of treatment showed a significant mean reduction of 64% (p<0.001) in serum neurofilament light (NfL) levels from baseline. The U.S. Food and Drug Administration (FDA) recently advised Denali to evaluate NfL as an exploratory endpoint to assess its potential as a biomarker for diagnosing, predicting outcomes, or gauging treatment response in individuals with neuronopathic MPS II. DNL310 is an investigational brain-penetrant enzyme replacement therapy aimed at addressing the behavioral, cognitive, and physical symptoms of MPS II. The global Phase 2/3 COMPASS study is currently ongoing.

 

Hunter Syndrome Overview

Hunter Syndrome, also known as Mucopolysaccharidosis II (MPS II), is a rare genetic disorder that affects the body’s ability to break down certain complex molecules called glycosaminoglycans (GAGs).

 

Get a Free Sample PDF Report to know more about Hunter Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hunter-syndrome-pipeline-insight

 

Emerging Hunter Syndrome Drugs Under Different Phases of Clinical Development Include:

  • CAP 001: Capsida Biotherapeutics

  • JR-141: JCR Pharmaceuticals

  • TAK-609/SHP609/HGT-2310: Takeda

  • GC1111 (Hunterase): Green Cross Corporation/GC Pharma

  • DNL310: Denali Therapeutics

  • RGX-121: Regenxbio

  • SB-913: Sangamo Therapeutics

  • AVR-RD-05: AVROBIO

 

Hunter Syndrome Route of Administration

Hunter Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Hunter Syndrome Molecule Type

Hunter Syndrome Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

Hunter Syndrome Pipeline Therapeutics Assessment

  • Hunter Syndrome Assessment by Product Type

  • Hunter Syndrome By Stage and Product Type

  • Hunter Syndrome Assessment by Route of Administration

  • Hunter Syndrome By Stage and Route of Administration

  • Hunter Syndrome Assessment by Molecule Type

  • Hunter Syndrome by Stage and Molecule Type

 

DelveInsight’s Hunter Syndrome Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Hunter Syndrome product details are provided in the report. Download the Hunter Syndrome pipeline report to learn more about the emerging Hunter Syndrome therapies

 

Some of the key companies in the Hunter Syndrome Therapeutics Market include:

Key companies developing therapies for Hunter Syndrome are – REGENXBIO Inc., Takeda Pharmaceutical Company Limited, Triley Bidco Limited (Clinigen Group PLC), JCR Pharmaceuticals, Sangamo Therapeutics, Denali Therapeutics Inc., Bioasis Technologies Inc., Inventiva, GC Pharma (Green Cross Holdings), Esteve, Avrobio Inc., CANbridge Life Sciences Ltd, and others.

 

Hunter Syndrome Pipeline Analysis:

The Hunter Syndrome pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hunter Syndrome with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hunter Syndrome Treatment.

  • Hunter Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Hunter Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hunter Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Hunter Syndrome drugs and therapies

 

Hunter Syndrome Pipeline Market Drivers

  • Increase in the number of the population suffering from hunter syndrome, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Hunter Syndrome Market.

 

Hunter Syndrome Pipeline Market Barriers

  • However, high cost of treatment, heterogeneity of the disease, lack of awareness and other factors are creating obstacles in the Hunter Syndrome Market growth.

 

Scope of Hunter Syndrome Pipeline Drug Insight    

  • Coverage: Global

  • Key Hunter Syndrome Companies: Capsida Biotherapeutics, JCR Pharmaceuticals, Takeda, Green Cross Corporation/GC Pharma, Denali Therapeutics, Regenxbio, Sangamo Therapeutics, AVROBIO, and others

  • Key Hunter Syndrome Therapies: CAP 001, JR-141, TAK-609/SHP609/HGT-2310, GC1111 (Hunterase), DNL310, RGX-121, SB-913, AVR-RD-05, and others

  • Hunter Syndrome Therapeutic Assessment: Hunter Syndrome current marketed and Hunter Syndrome emerging therapies

  • Hunter Syndrome Market Dynamics: Hunter Syndrome market drivers and Hunter Syndrome market barriers 

 

Request for Sample PDF Report for Hunter Syndrome Pipeline Assessment and clinical trials

 

Table of Contents 

1. Hunter Syndrome Report Introduction

2. Hunter Syndrome Executive Summary

3. Hunter Syndrome Overview

4. Hunter Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Hunter Syndrome Pipeline Therapeutics

6. Hunter Syndrome Late Stage Products (Phase II/III)

7. Hunter Syndrome Mid Stage Products (Phase II)

8. Hunter Syndrome Early Stage Products (Phase I)

9. Hunter Syndrome Preclinical Stage Products

10. Hunter Syndrome Therapeutics Assessment

11. Hunter Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hunter Syndrome Key Companies

14. Hunter Syndrome Key Products

15. Hunter Syndrome Unmet Needs

16 . Hunter Syndrome Market Drivers and Barriers

17. Hunter Syndrome Future Perspectives and Conclusion

18. Hunter Syndrome Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hunter Syndrome Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | REGENXBIO, Takeda, Triley Bidco, JCR Pharma, Sangamo Therapeutics

Torque Ball Revolutionizes Hand and Wrist Pain Relief with Innovative Gyroscopic Technology

Torque Ball, the innovative hand-held therapy device, is revolutionizing the way individuals manage hand and wrist pain. With an astounding number of over 2,000 verified reviews and an impressive 4.9-star rating, Torque Ball is currently offering an exclusive 57% discount for a limited time, providing an unprecedented opportunity for individuals to experience the transformative power of drug-free pain relief.

Tired of Living with Hand Pain? Discover a Natural Solution!

Millions of people across the globe grapple with persistent hand and wrist discomfort stemming from a variety of causes, including repetitive stress injuries, arthritis, and carpal tunnel syndrome. Torque Ball emerges as a beacon of hope, offering a natural, non-invasive solution that harnesses the remarkable power of gyroscopic motion to activate muscles, promote the body’s natural healing processes, and enhance flexibility.

Key Benefits of Torque Ball: Your Path to Pain-Free Hands

  • Fast-Acting Pain Relief: Users consistently report experiencing a noticeable reduction in pain within minutes of incorporating Torque Ball into their daily routine. The device’s unique design and targeted approach provide swift relief from discomfort and stiffness.
  • Customizable Intensity: Recognizing that every individual’s pain journey is unique, Torque Ball offers multiple intensity levels, allowing users to tailor their experience to their specific needs. Whether seeking gentle relief or a deeper tissue massage, Torque Ball caters to all levels of discomfort.
  • Portable and Convenient: Designed with the modern lifestyle in mind, Torque Ball boasts a compact and lightweight design, making it the perfect companion for home, work, or travel. Pain relief is now accessible anytime, anywhere.
  • Affordable and Effective: In a world where medical treatments can often be costly and invasive, Torque Ball stands out as a cost-effective and holistic solution. Say goodbye to expensive therapies and embrace a natural approach to pain management.
  • Gyroscopic Power Deep Relief: Feel an instant wave of soothing relief as Torque Ball’s internal mechanism gently activates the muscles in your hands and wrists, promoting blood flow and accelerating the healing process.
  • Savings That Soothe: Replace endless doctor visits, pricey physical therapy sessions, and ineffective wrist braces with a one-time purchase that provides long-lasting relief and empowers you to take control of your health.

Limited Time Offer! Don’t Miss Out on Unprecedented Savings!

For a limited time only, Torque Ball is offering an exclusive 57% discount, making this cutting-edge technology more accessible than ever before. This unprecedented offer is a testament to Torque Ball‘s commitment to helping individuals break free from the shackles of pain and rediscover the joy of living.

About Torque Ball: The Future of Pain Relief

Torque Ball represents the forefront of pain relief technology, combining innovation with a deep understanding of the human body. Its gyroscopic motion technology delivers a targeted deep tissue massage that stimulates muscle activation, promotes blood flow, and accelerates the healing process. With thousands of satisfied customers worldwide, Torque Ball is rapidly establishing itself as the premier choice for individuals seeking a natural and effective path to pain-free living.

Learn More and Claim Your Discount!

To embark on your journey to a pain-free life and take advantage of the exclusive 57% discount, visit TorqueBall.com. Don’t miss out on this limited-time opportunity to transform your health and well-being.

Media Contact
Company Name: TorqueBall
Contact Person: Kerry Jensen
Email: Send Email
Address:5900 Balcones Drive Suite 100
City: Austin
State: Texas
Country: United States
Website: www.torqueball.com/new/?gclid=ab2

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Torque Ball Revolutionizes Hand and Wrist Pain Relief with Innovative Gyroscopic Technology

Polycythemia Vera Pipeline Insights 2024: Therapies, Clinical Trials, and Clinical Trials | F. Hoffmann-La Roche, Fujifilm Holdings Corp, Hangzhou Bensheng Pharma, Protagonist Therapeutics, Ascentage

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Polycythemia Vera pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia Vera treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Polycythemia Vera Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Polycythemia Vera Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Polycythemia Vera Market.

 

Some of the key takeaways from the Polycythemia Vera Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Polycythemia Vera treatment therapies with a considerable amount of success over the years. 

  • Polycythemia Vera companies working in the treatment market are Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others, are developing therapies for the Polycythemia Vera treatment 

  • Emerging Polycythemia Vera therapies in the different phases of clinical trials are- Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others are expected to have a significant impact on the Polycythemia Vera market in the coming years.   

  • In February 2024, Disc Medicine has disclosed that the US FDA has awarded Orphan Drug Designation to DISC-3405 for treating patients with PV. Additionally, in September 2023, the FDA granted fast track designation to MWTX-003, also known as DISC-3405, for PV treatment.

  • In January 2024, Takeda and Protagonist Therapeutics have established a global licensing and collaboration agreement for rusfertide.

  • In September 2023, NICE has endorsed Novartis’s JAKAVI (ruxolitinib) for individuals diagnosed with PV.

 

Polycythemia Vera Overview

Polycythemia vera (PV) is a rare blood disorder characterized by the overproduction of red blood cells in the bone marrow. This overproduction leads to thickening of the blood, which can slow its flow and increase the risk of clotting.

 

Get a Free Sample PDF Report to know more about Polycythemia Vera Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight

 

Emerging Polycythemia Vera Drugs Under Different Phases of Clinical Development Include:

  • Rusfertide (PTG-300): Protagonist Therapeutics

  • Givinostat (ITF2357): Italfarmaco

  • Bomedemstat: Imago BioSciences

  • SLN124: Silence Therapeutics

  • Sapablursen: Ionis Pharmaceutical

  • PPMX-T003: Perseus Proteomics

  • PTG-300: Protagonist Therapeutics, Inc.

  • SLN124: Silence Therapeutics plc

  • Hydroxyurea: Novartis

  • Ropeginterferon alfa-2b: PharmaEssentia

  • PEG-P-INF alpha-2b (P1101): AOP Orphan Pharmaceuticals AG

  • Ruxolitinib: Incyte Corporation

 

Polycythemia Vera Route of Administration

Polycythemia Vera pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

 

Polycythemia Vera Molecule Type

Polycythemia Vera Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule

 

Polycythemia Vera Pipeline Therapeutics Assessment

  • Polycythemia Vera Assessment by Product Type

  • Polycythemia Vera By Stage and Product Type

  • Polycythemia Vera Assessment by Route of Administration

  • Polycythemia Vera By Stage and Route of Administration

  • Polycythemia Vera Assessment by Molecule Type

  • Polycythemia Vera by Stage and Molecule Type

 

DelveInsight’s Polycythemia Vera Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Polycythemia Vera product details are provided in the report. Download the Polycythemia Vera pipeline report to learn more about the emerging Polycythemia Vera therapies

 

Some of the key companies in the Polycythemia Vera Therapeutics Market include:

Key companies developing therapies for Polycythemia Vera are – F. Hoffmann-La Roche Ltd, Fujifilm Holdings Corp, Hangzhou Bensheng Pharmaceutical Co Ltd, Protagonist Therapeutics Inc, Ascentage Pharma Group International, Imago BioSciences Inc, and Ionis Pharmaceuticals Inc, and others.

 

Polycythemia Vera Pipeline Analysis:

The Polycythemia Vera pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Polycythemia Vera with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycythemia Vera Treatment.

  • Polycythemia Vera key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Polycythemia Vera Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycythemia Vera market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Polycythemia Vera drugs and therapies

 

Polycythemia Vera Pipeline Market Strengths

  • The approval of BESREMi in the US and its expected approval in Japan, in both the first and second line of treatment, provides the interferon with an immense opportunity to garner a big market size in Polycythemia Vera. 

  • Based on increasing sales of JAKAFI/JAKAVI, the drug will be a blockbuster therapy in 2L PV patients

 

Polycythemia Vera Pipeline Market Opportunities

  • An increase in strategic alliances, such as geographical alliances, and granting the designation such as BTD and FTD by the FDA are some of the factors that will drive the market growth.

  • Opportunity for drugs with novel and disease-modifying mechanisms and low side effect.

 

Scope of Polycythemia Vera Pipeline Drug Insight    

  • Coverage: Global

  • Key Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others

  • Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others

  • Polycythemia Vera Therapeutic Assessment: Polycythemia Vera current marketed and Polycythemia Vera emerging therapies

  • Polycythemia Vera Market Dynamics: Polycythemia Vera market drivers and Polycythemia Vera market barriers 

 

Request for Sample PDF Report for Polycythemia Vera Pipeline Assessment and clinical trials

 

Table of Contents

1. Polycythemia Vera Report Introduction

2. Polycythemia Vera Executive Summary

3. Polycythemia Vera Overview

4. Polycythemia Vera- Analytical Perspective In-depth Commercial Assessment

5. Polycythemia Vera Pipeline Therapeutics

6. Polycythemia Vera Late Stage Products (Phase II/III)

7. Polycythemia Vera Mid Stage Products (Phase II)

8. Polycythemia Vera Early Stage Products (Phase I)

9. Polycythemia Vera Preclinical Stage Products

10. Polycythemia Vera Therapeutics Assessment

11. Polycythemia Vera Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Polycythemia Vera Key Companies

14. Polycythemia Vera Key Products

15. Polycythemia Vera Unmet Needs

16 . Polycythemia Vera Market Drivers and Barriers

17. Polycythemia Vera Future Perspectives and Conclusion

18. Polycythemia Vera Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Polycythemia Vera Pipeline Insights 2024: Therapies, Clinical Trials, and Clinical Trials | F. Hoffmann-La Roche, Fujifilm Holdings Corp, Hangzhou Bensheng Pharma, Protagonist Therapeutics, Ascentage

Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insights | Alexza Pharma, Xenon Pharma, GW Pharma, Equilibre Biopharma, Takeda Pharma, Abide therapeutics, Otsuka pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Epilepsy Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market.

 

Some of the key takeaways from the Epilepsy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years. 

  • Epilepsy companies working in the treatment market are Elium Therapeutics, CombiGene, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc, and others, are developing therapies for the Epilepsy treatment 

  • Emerging Epilepsy therapies in the different phases of clinical trials are- Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, RLS103, CT-010, EQU 001, Darigabat, ENX-101, AMZ002, XEN496, and others are expected to have a significant impact on the Epilepsy market in the coming years.   

  • In January 2023, In order to assess the efficacy and safety of AMZ002 in the treatment of infantile spasms, a rare form of epilepsy, Amzell started a randomised, open-label superiority study. The primary goal of this study is to compare AMZ002 and Vigabatrin for treating infantile spasms (IS) in participants who have just received a diagnosis

  • In March 2023, Preclinical data supporting IAMA Therapeutics’ IAMA-6 programme in focal refractory epilepsy will be presented at the 75th American Academy of Neurology (AAN) Annual Meeting, which will be held from April 22–27 in Boston, Massachusetts. IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to improve the lives of people suffering from brain disorders

  • In February 2023, The Phase 2 clinical study of ADX71149 (JNJ-40411813) for the treatment of epilepsy was completed, according to an announcement from Addex Therapeutics. Metabotropic glutamate type 2 (mGlu2) receptor-positive allosteric modulator (PAM) ADX71149 is selective. The experiment is being run by Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson’s Janssen Pharmaceutical Companies

  • In January 2023, EQU-001, a novel anti-inflammatory anti-seizure drug, is administered as once-daily oral adjunctive therapy for focal seizures in adults with epilepsy. Equilibre Biopharmaceuticals Corp. reported positive topline results from the Phase 2 clinical trial evaluating the clinical safety, tolerability, and preliminary efficacy of EQU-001. The EQU-001 study’s findings are positive since they show outstanding tolerability and encouraging efficacy for adult patients with focal epilepsy, particularly for those who have seizures that are challenging to manage.

 

Epilepsy Overview

A chronic neurological condition called epilepsy is characterised by frequent, recurrent convulsions that cause strange behaviour. Due to the many seizure forms, underlying conditions, and varying degrees of severity, it might be seen as a spectrum disorder.

 

Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/epilepsy-pipeline-insight

 

Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include:

  • Kv7 Program: Elium Therapeutics

  • CG 01: CombiGene

  • OV329: Ovid Therapeutics

  • OPC-214870: Otsuka Pharmaceutical Co.,Ltd.

  • SKL24741: SK Biopharmaceuticals

  • RLS103: Receptor Life Sciences

  • CT-010: Cerebral Therapeutics

  • EQU 001: Equilibre Biopharmaceuticals

  • Darigabat: Cerevel Therapeutics

  • ENX-101: Engrail Therapeutics

  • AMZ002: Amzell

  • XEN496: Xenon Pharmaceuticals Inc

 

Epilepsy Route of Administration

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Epilepsy Molecule Type

Epilepsy Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy 

 

Epilepsy Pipeline Therapeutics Assessment

  • Epilepsy Assessment by Product Type

  • Epilepsy By Stage and Product Type

  • Epilepsy Assessment by Route of Administration

  • Epilepsy By Stage and Route of Administration

  • Epilepsy Assessment by Molecule Type

  • Epilepsy by Stage and Molecule Type

 

DelveInsight’s Epilepsy Report covers around 90+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies

 

Some of the key companies in the Epilepsy Therapeutics Market include:

Key companies developing therapies for Epilepsy are – Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, H. Lundbeck A/S, Spark Therapeutics,  Equilibre Biopharmaceuticals,  ES Therapeutics, Supernus Pharmaceuticals, Inc., MGC Pharmaceuticals, Engrail Therapeutics INC, SK biopharmaceuticals, Longboard Pharmaceuticals, Janssen Research & Development, LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, LLC, Neurona Therapeutics, Praxis Precision Medicines, UCB Pharma, Receptor Life Sciences, NeuroPro Therapeutics, Inc., Avicanna, Amring Pharmaceuticals Inc., Ovid Therapeutics, Addex Therapeutics, IAMA Therapeutics, CODA Biotherapeutics,  Cerebral Therapeutics, Engrail Therapeutics, and others.

 

Epilepsy Pipeline Analysis:

The Epilepsy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.

  • Epilepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Epilepsy drugs and therapies

 

Epilepsy Pipeline Market Drivers

  • Rising awareness and strategic alliance, increasing launch of novel drugs, high burden of epilepsy are some of the important factors that are fueling the Epilepsy Market.

 

Epilepsy Pipeline Market Barriers

  • However, loss of patent protection for branded drugs, high cost of treatment and other factors are creating obstacles in the Epilepsy Market growth.

 

Scope of Epilepsy Pipeline Drug Insight    

  • Coverage: Global

  • Key Epilepsy Companies: Elium Therapeutics, CombiGene, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc, and others

  • Key Epilepsy Therapies: Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, RLS103, CT-010, EQU 001, Darigabat, ENX-101, AMZ002, XEN496, and others

  • Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies

  • Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers 

 

Request for Sample PDF Report for Epilepsy Pipeline Assessment and clinical trials

 

Table of Contents 

1. Epilepsy Report Introduction

2. Epilepsy Executive Summary

3. Epilepsy Overview

4. Epilepsy- Analytical Perspective In-depth Commercial Assessment

5. Epilepsy Pipeline Therapeutics

6. Epilepsy Late Stage Products (Phase II/III)

7. Epilepsy Mid Stage Products (Phase II)

8. Epilepsy Early Stage Products (Phase I)

9. Epilepsy Preclinical Stage Products

10. Epilepsy Therapeutics Assessment

11. Epilepsy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Epilepsy Key Companies

14. Epilepsy Key Products

15. Epilepsy Unmet Needs

16 . Epilepsy Market Drivers and Barriers

17. Epilepsy Future Perspectives and Conclusion

18. Epilepsy Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insights | Alexza Pharma, Xenon Pharma, GW Pharma, Equilibre Biopharma, Takeda Pharma, Abide therapeutics, Otsuka pharma